The prescription experience has started to resemble other parts of digital commerce: shoppers want clear pricing, fewer handoffs and a quicker path from decision to fulfillment.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional login ...

The stock’s decline follows a report that revealed revenue missed analyst expectations, adding pressure as broader markets experienced slight gains on the previous trading day.HIMS Q4 Earnings Miss Revenue ForecastsHims & Hers Health reported fourth-quarter revenue of $617.82 million, falling short of analyst estimates of $619.22 million. However, the company did beat earnings expectations with a reported 8 cents per share, surpassing estimates of 3 cents per share.The company noted that total revenue was u ...

The partnership will expand accessibility to Alberta Health-covered care, providing residents with access to licensed Alberta physicians virtually, from the location of their choice, with no user fees.Rocket Doctor’s platform will be tailored to Lethbridge County residents, supporting a wide range of needs including urgent care, chronic condition management / primary care, and mental health services.This collaboration addresses critical primary and urgent care gaps in rural communities, particularly for res ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

SAN RAMON, Calif.--(BUSINESS WIRE)-- #PregnancyJourney--MediKarma, the AI-driven platform that unifies and activates patient data to drive proactive care, today announced it has successfully completed the acquisition of Nanell, a specialized digital solution focused on the pregnancy journey, from Niterra Co., Ltd (Headquarters: Nagoya, Japan). The acquisition is set to integrate Nanell's intellectual property, product assets and operations directly into MediKarma's platform, strengthening its offering in Wo ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is establishing itself as a leading digital health platform focused on personalized, technology-enabled care, expanding its offerings across various life stages and health conditions [1][8] - The company has launched new specialties in women's health, including menopause and perimenopause, and in men's health with a low testosterone category, providing tailored treatment plans [1][8] - Hims & Hers is advancing into proactive, data-driven care with the introduction of Labs for comprehensive health monitoring and a multi-cancer early detection blood test [2][8] Company Developments - Hims & Hers has introduced a dedicated menopause and perimenopause specialty on the Hers platform, along with a low testosterone category on the HIMS platform, enhancing its service offerings [1][8] - The launch of Labs allows customers to monitor key health markers over time, supported by provider-guided action plans, and includes a multi-cancer early detection blood test for over 50 cancer types [2][8] - The company is making strategic investments in AI, diagnostics, and global expansion to create a connected healthcare platform that prioritizes personalized, preventive care [2][8] Financial Performance - Hims & Hers shares have decreased by 67.9% over the past year, underperforming the industry average decline of 32.8% [7] - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a significant improvement of 77.8% compared to 2024 [9] - HIMS' forward 12-month price-to-sales ratio is 1.3X, which is lower than the industry average of 3.7X and its five-year median of 2.7X, reflecting a Value Score of C [11]

7,111,969-$1.715.45%$29.68[Oracle][ORCL]• Vol: 10,510,788-$6.123.91%$150.43[Copart][CPRT]• Vol: 10,973,155-$1.473.90%$36.18[Newmont][NEM]• Vol: 5,055,402-$4.533.61%$120.87 Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills? - 24/7 Wall St.[S&P 5006,905.00 +0.65%][Dow Jones49,505.00 +0.28%][Nasdaq 10025,049.60 +1.07%][Russell 20002,662.73 +0.01%][FTSE 10010,708.60 +0.26%][Nikkei 22557,158.00 +0.12%][Stock Market Live February 20, 2026: S&P 500 (SPY) Sinks on US GDP Numbers][Investing]# ...

Core Insights - iRhythm Holdings, Inc. reported strong financial results for Q4 and full year 2025, marking a transformational year with significant revenue growth and positive net income for the first time in its history [4][10]. Financial Highlights Fourth Quarter 2025 - Revenue increased by 27.1% to $208.9 million compared to $164.3 million in Q4 2024, driven by higher demand for Zio Services [5][8]. - Gross profit rose to $148.1 million, up from $115.1 million in Q4 2024, with a gross margin of 70.9%, an improvement from 70.0% [6][8]. - Net income for Q4 2025 was $5.6 million, a significant improvement from a net loss of $1.3 million in Q4 2024 [9][8]. - Adjusted EBITDA was $34.3 million, with an adjusted EBITDA margin of 16.4%, reflecting a $15.0 million increase compared to Q4 2024 [8]. Full Year 2025 - Total revenue for 2025 reached $747.1 million, a 26.2% increase from $591.8 million in 2024 [10][11]. - Gross profit for the year was $527.3 million, up from $407.5 million in 2024, with a gross margin of 70.6%, improving from 68.9% [11]. - The net loss for 2025 was $44.6 million, a $68.7 million improvement compared to a net loss of $113.3 million in 2024 [12][10]. - Free cash flow for 2025 was $34.5 million, marking the first year of positive free cash flow in the company's history [8]. Operational Highlights - The company emphasized the growing demand for Zio across various healthcare sectors, highlighting its ability to provide proactive, data-driven arrhythmia detection [4]. - iRhythm plans to scale its platform globally, advance its product roadmap, and enhance its predictive AI capabilities while maintaining financial discipline [4]. 2026 Guidance - For 2026, iRhythm expects revenue between $870 million and $880 million, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued growth and operational efficiency [13].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...